Biogen (BIIB) Misses Q1 EPS by 76c, Announces CEO Transition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $250.69 -1.24%
Revenue Growth %: +4.3%
Financial Fact:
Total cost and expenses: 1.53B
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: +4.3%
Financial Fact:
Total cost and expenses: 1.53B
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q1 EPS of $3.62, $0.76 worse than the analyst estimate of $4.38. Revenue for the quarter came in at $2.53 billion versus the consensus estimate of $2.5 billion.
- Announces CEO Transition
- Reaffirms FY Guidance
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Tompkins Financial (TMP) Tops Q3 EPS by 5c
- Biogen (BIIB) PT Raised to $250 at TD Cowen
Create E-mail Alert Related Categories
Corporate News, Earnings, Hot Corp. News, Hot Earnings, Hot Mgmt Changes, Management ChangesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
